Learning Objectives:

1.Understand how the pathophysiology and genetics of CML led to the development of target therapies

2.Learn the patient outcomes from treatment for CML with BCR-ABL1 tyrosine kinase inhibitors

Session date: 
06/18/2024 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Richard Larson, MD